Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma (using the specific medical code C90.00), where the diagnosis was confirmed by a medical professional reviewing their records, and occurred after the formal launch of the MRD-targeted clinical pathway in the Exigent network.
- People who were 18 years of age or older at the time of their multiple myeloma diagnosis.
- People who have continued receiving care at a QCCA/Exigent Research practice for at least 90 days after their diagnosis date.
- (For the Documentation Cohort only) People whose medical records show evidence that they have followed, or intended to follow, the specific clinical treatment pathway used in this trial (confirm with trial site).
- (For the Platform Cohort only) People who have registered to participate in the All4Cure platform, including signing the required forms that allow All4Cure to access their medical records, and whose primary treating doctor has also registered for the All4Cure platform.
Who may not be able to join:
- People who have another active cancer diagnosis at the same time (exceptions may apply for certain skin cancers — basal cell carcinoma, squamous cell carcinoma of the skin — or early-stage breast or cervical cancers; confirm with trial site), or who received treatment for another cancer within the three years before their multiple myeloma diagnosis (with the same exceptions).
- People whose multiple myeloma is of a rare subtype known as IgD or IgE myeloma.
- People who moved their ongoing cancer care to a facility outside the QCCA/Exigent Research network within the first 90 days after being diagnosed with multiple myeloma.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (425) 477-9021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To compare rate of tumor response and complete tumor response (≥VGPR and ≥CR) within 12 months of start of front-line therapy between the Documentation and Off-Pathway COHORT groups.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.